David Y. Liu - Aug 17, 2021 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role: Chief Scientific Officer
Signature: /s/ David Y. Liu
Stock symbol: PTGX
Transactions as of: Aug 17, 2021
Transactions value $: -$694,189
Form type: 4
Date filed: 8/19/2021, 05:49 PM
Next filing: Feb 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTGX	Common Stock	Options Exercise	$8.7K	+10K	+15.86%	$0.87^*	73K	Aug 17, 2021	Direct	F1
transaction	PTGX	Common Stock	Sale	-$703K	-14.8K	-20.24%	$47.56	58.3K	Aug 17, 2021	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTGX	Stock Option (right to buy)	Options Exercise	$0	-10K	-42.08%	$0.00	13.8K	Aug 17, 2021	Common Stock	10K	$0.87	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes an aggregate of 606 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 7, 2021.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.10 to $48.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	The stock option is vested in full.